{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:51:37Z","timestamp":1791395497772,"version":"4.3.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01256-7","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:00:06Z","timestamp":1791392406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast"],"prefix":"10.1007","author":[{"given":"Shailender","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"9","key":"1256_CR1","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-17-0439","volume":"24","author":"A Colunga","year":"2018","unstructured":"Colunga A, Pulliam T, Nghiem P. Merkel cell carcinoma in the age of immunotherapy: Facts and hopes. Clin Cancer Res. 2018;24(9):2035\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0439.","journal-title":"Clin Cancer Res"},{"key":"1256_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","volume":"71","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Lebbe C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53\u201369. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.022.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1256_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11912-025-01693-z","volume":"27","author":"K Pan","year":"2025","unstructured":"Pan K, Vromans AM, Cheng L, Grant-Kels JM, Katz SC, Hadfield MJ. Merkel cell carcinoma: current treatment landscape and emerging therapeutic targets. Curr Oncol Rep. 2025;27(7):822\u201332. https:\/\/doi.org\/10.1007\/s11912-025-01693-z.","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"1256_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamadermatol.2014.124","volume":"150","author":"DR Youlden","year":"2014","unstructured":"Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993\u20132010. JAMA Dermatol. 2014;150(8):864\u201372. https:\/\/doi.org\/10.1001\/jamadermatol.2014.124.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1256_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","volume":"58","author":"M Heath","year":"2008","unstructured":"Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58(3):375\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2007.11.020.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1256_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000654","volume":"4","author":"E Gong","year":"2025","unstructured":"Gong E, Zawacki L, Fan X, Hippe DS, Menon AA, Remington AJ, et al. Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients. BMJ Oncol. 2025;4(1):e000654. https:\/\/doi.org\/10.1136\/bmjonc-2024-000654.","journal-title":"BMJ Oncol"},{"issue":"14","key":"1256_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/cancers17142340","volume":"17","author":"T Patel","year":"2025","unstructured":"Patel T, Butz R, Boulmay B, Vaitaitis V. Current trends in clinical trials for Merkel cell carcinoma (MCC). Cancers (Basel). 2025;17(14):2340.\u00a0https:\/\/doi.org\/10.3390\/cancers17142340.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1256_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","volume":"158","author":"AM McEvoy","year":"2022","unstructured":"McEvoy AM, Lachance K, Hippe DS, Cahill K, Moshiri Y, Lewis CW, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2021.6096.","journal-title":"JAMA Dermatol"},{"key":"1256_CR9","unstructured":"Drugs.com. FDA approval history. https:\/\/www.drugs.com\/history\/."},{"issue":"1","key":"1256_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2025.03.006","volume":"93","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Park SY, Bhatia S, Hippe DS, Nghiem P. Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy. J Am Acad Dermatol. 2025;93(1):89\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.006.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1256_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1256_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000674","volume":"8","author":"SP D\u2019Angelo","year":"2020","unstructured":"D\u2019Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8(1):e000674. https:\/\/doi.org\/10.1136\/jitc-2020-000674.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1256_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100290","volume":"6","author":"SP D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021;6(6):100290. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100290.","journal-title":"ESMO Open."},{"issue":"7","key":"1256_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002646","volume":"9","author":"SP D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo SP, Lebbe C, Mortier L, Brohl AS, Fazio N, Grob JJ, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021;9(7):e002646. https:\/\/doi.org\/10.1136\/jitc-2021-002646.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1256_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103461","volume":"9","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Lebb\u00e9 C, Mortier L, Brohl AS, Fazio N, Grob JJ, et al. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open. 2024;9(5):103461. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103461.","journal-title":"ESMO Open"},{"issue":"26","key":"1256_CR16","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1603702.","journal-title":"N Engl J Med"},{"issue":"9","key":"1256_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693\u2013702. https:\/\/doi.org\/10.1200\/JCO.18.01896.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1256_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002478","volume":"9","author":"P Nghiem","year":"2021","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9(4):e002478. https:\/\/doi.org\/10.1136\/jitc-2021-002478.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1256_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40257-024-00885-w","volume":"25","author":"L Mortier","year":"2024","unstructured":"Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, et al. Pembrolizumab for the first-line treatment of recurrent locally advanced or metastatic Merkel cell carcinoma: results from the single-arm, open-label, phase III KEYNOTE-913 study. Am J Clin Dermatol. 2024;25(6):987\u201396. https:\/\/doi.org\/10.1007\/s40257-024-00885-w.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1256_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012478","volume":"13","author":"G Grignani","year":"2025","unstructured":"Grignani G, Rutkowski P, Lebbe C, Guida M, Gaudy-Marqueste C, Spagnolo F, et al. Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). J Immunother Cancer. 2025;13(8):e012478. https:\/\/doi.org\/10.1136\/jitc-2025-012478.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1256_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1200\/JCO-24-02138","volume":"43","author":"S Bhatia","year":"2025","unstructured":"Bhatia S, Topalian SL, Sharfman W, Meyer T, Steven N, Lao CD, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma: a nonrandomized, open-label, international, multicenter phase I\/II study. J Clin Oncol. 2025;43(9):1137\u201347. https:\/\/doi.org\/10.1200\/JCO-24-02138.","journal-title":"J Clin Oncol"},{"issue":"10357","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022;400(10357):1008\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01659-2.","journal-title":"Lancet"},{"key":"1256_CR23","doi-asserted-by":"publisher","unstructured":"Kearney M, Kwon CS, Lan Z, Rutherford M, Moradian H, Freitag A. Systematic literature review and meta-analysis of the real-world effectiveness and safety of avelumab in patients with locally advanced or metastatic Merkel cell carcinoma (MCC). Value Health. 2024;27(12):S34 (abstract CO108). https:\/\/doi.org\/10.1016\/j.jval.2024.10.184.","DOI":"10.1016\/j.jval.2024.10.184"},{"key":"1256_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/POR.S398151","volume":"14","author":"R Lohray","year":"2023","unstructured":"Lohray R, Verma KK, Wang LL, Haynes D, Lewis DJ. Avelumab for advanced Merkel cell carcinoma: global real-world data on patient response and survival. Pragmat Obs Res. 2023;14:149\u201354. https:\/\/doi.org\/10.2147\/POR.S398151.","journal-title":"Pragmat Obs Res."},{"key":"1256_CR25","doi-asserted-by":"publisher","unstructured":"Becker JC, Mahmoudpour S, Schadendorf D, Leiter-Stoppke U, Meier F, Herbst R, et al. Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: analysis of a prospective German MCC registry (MCC TRIM). Ann Oncol. 2023;34(Suppl 2):S685\u20136 (abstract 1145P). https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2279.","DOI":"10.1016\/j.annonc.2023.09.2279"},{"issue":"8","key":"1256_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004904","volume":"10","author":"S Bhatia","year":"2022","unstructured":"Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022;10(8):e004904. https:\/\/doi.org\/10.1136\/jitc-2022-004904.","journal-title":"J Immunother Cancer"},{"issue":"18","key":"1256_CR27","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2217\/fon-2020-1250","volume":"17","author":"CL Cowey","year":"2021","unstructured":"Cowey CL, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S, et al. Real-world clinical outcomes with first-line avelumab in locally advanced\/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Future Oncol. 2021;17(18):2339\u201350. https:\/\/doi.org\/10.2217\/fon-2020-1250.","journal-title":"Future Oncol"},{"issue":"2","key":"1256_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001076","volume":"8","author":"S Levy","year":"2020","unstructured":"Levy S, Aarts MJB, Eskens F, Keymeulen K, Been LB, Gr\u00fcnhagen D, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer. 2020;8(2):e001076. https:\/\/doi.org\/10.1136\/jitc-2020-001076.","journal-title":"J Immunother Cancer"},{"key":"1256_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114261","volume":"209","author":"L Mortier","year":"2024","unstructured":"Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, et al. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. Eur J Cancer. 2024;209:114261. https:\/\/doi.org\/10.1016\/j.ejca.2024.114261.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1256_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1346-8138.17096","volume":"51","author":"H Uhara","year":"2024","unstructured":"Uhara H, Kiyohara Y, Isei T, Nagase K, Kambe A, Sato M, et al. Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: post-marketing surveillance. J Dermatol. 2024;51(4):475\u201383. https:\/\/doi.org\/10.1111\/1346-8138.17096.","journal-title":"J Dermatol"},{"issue":"1","key":"1256_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000313","volume":"8","author":"JW Walker","year":"2020","unstructured":"Walker JW, Lebb\u00e9 C, Grignani G, Nathan P, Dirix L, Fenig E, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020;8(1):e000313. https:\/\/doi.org\/10.1136\/jitc-2019-000313.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1256_CR32","doi-asserted-by":"publisher","first-page":"e012123","DOI":"10.1136\/jitc-2025-012123","volume":"13","author":"L Tachiki","year":"2025","unstructured":"Tachiki L, Moshiri Y, Hippe DS, Gong E, Zawacki L, Pulliam T, et al. Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade. J Immunother Cancer. 2025;13(8):e012123.\u00a0https:\/\/doi.org\/10.1136\/jitc-2025-012123.","journal-title":"J Immunother Cancer"},{"key":"1256_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2023.01.016","volume":"183","author":"AM Weppler","year":"2023","unstructured":"Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, et al. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. Eur J Cancer. 2023;183:109\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.016.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1256_CR34","doi-asserted-by":"publisher","first-page":"e009816","DOI":"10.1136\/jitc-2024-009816","volume":"12","author":"T Ramadoss","year":"2024","unstructured":"Ramadoss T, Nichols M, Palacios C, Eroglu Z, Markowitz J, Karapetyan L, et al. Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. J Immunother Cancer. 2024;12(9):e009816. https:\/\/doi.org\/10.1136\/jitc-2024-009816.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1256_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/cncr.35050","volume":"130","author":"LP Zijlker","year":"2024","unstructured":"Zijlker LP, Levy S, Wolters W, van Thienen JV, van Akkooi ACJ, Tesselaar MET. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET\/CT-confirmed complete response. Cancer. 2024;130(3):433\u20138. https:\/\/doi.org\/10.1002\/cncr.35050.","journal-title":"Cancer"},{"issue":"11","key":"1256_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, et al. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. 2020;17(11):707\u201315. https:\/\/doi.org\/10.1038\/s41571-020-0399-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1256_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0450-7","volume":"6","author":"NJ Miller","year":"2018","unstructured":"Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, et al. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. J Immunother Cancer. 2018;6(1):131. https:\/\/doi.org\/10.1186\/s40425-018-0450-7.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1256_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jid.2016.10.028","volume":"137","author":"AS Moshiri","year":"2017","unstructured":"Moshiri AS, Doumani R, Yelistratova L, Blom A, Lachance K, Shinohara MM, et al. Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol. 2017;137(4):819\u201327. https:\/\/doi.org\/10.1016\/j.jid.2016.10.028.","journal-title":"J Invest Dermatol"},{"issue":"21","key":"1256_CR39","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.3390\/cancers17213508","volume":"17","author":"P Vaidya","year":"2025","unstructured":"Vaidya P, Wu S, Bryant D, Perry CJ, Prakash V, Lou E, et al. Molecular characterization of polyomavirus-positive and negative Merkel cell carcinoma. Cancers (Basel). 2025;17(21):3508. https:\/\/doi.org\/10.3390\/cancers17213508.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1256_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamadermatol.2024.4607","volume":"161","author":"JT Tribble","year":"2025","unstructured":"Tribble JT, Pfeiffer RM, Brownell I, Cahoon EK, Sargen MR, Shiels MS, et al. Merkel cell carcinoma and immunosuppression, UV radiation, and Merkel cell polyomavirus. JAMA Dermatol. 2025;161(1):47\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4607.","journal-title":"JAMA Dermatol"},{"issue":"5866","key":"1256_CR41","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.1152586","volume":"319","author":"H Feng","year":"2008","unstructured":"Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096\u2013100. https:\/\/doi.org\/10.1126\/science.1152586.","journal-title":"Science"},{"issue":"6","key":"1256_CR42","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/bjd\/ljaf304","volume":"193","author":"T Akaike","year":"2025","unstructured":"Akaike T, Ch\u2019en PY, Hippe DS, Gilmour MW, Gong E, Fu A, et al. Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy. Br J Dermatol. 2025;193(6):1221\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljaf304.","journal-title":"Br J Dermatol"},{"key":"1256_CR43","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Merkel Cell Carcinoma. v2 2026."},{"issue":"5","key":"1256_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102977","volume":"9","author":"I Lugowska","year":"2024","unstructured":"Lugowska I, Becker JC, Ascierto PA, Veness M, Blom A, Lebbe C, et al. Merkel-cell carcinoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2024;9(5):102977. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102977.","journal-title":"ESMO Open"},{"issue":"8","key":"1256_CR45","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.jid.2026.01.021","volume":"146","author":"R Alam","year":"2026","unstructured":"Alam R, Menon AA, Ch\u2019en PY, Jabbour AJ, Gooley TA, Hippe DS, et al. Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: a 27-patient analysis. J Invest Dermatol. 2026;146(8):2168-75 e1. https:\/\/doi.org\/10.1016\/j.jid.2026.01.021.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1256_CR46","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/cam4.458","volume":"4","author":"JG Iyer","year":"2015","unstructured":"Iyer JG, Parvathaneni U, Gooley T, Miller NJ, Markowitz E, Blom A, et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med. 2015;4(8):1161\u201370. https:\/\/doi.org\/10.1002\/cam4.458.","journal-title":"Cancer Med"},{"issue":"7","key":"1256_CR47","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00262-020-02832-0","volume":"70","author":"V Glutsch","year":"2021","unstructured":"Glutsch V, Kneitz H, Gesierich A, Goebeler M, Haferkamp S, Becker JC, et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. Cancer Immunol Immunother. 2021;70(7):2087\u201393. https:\/\/doi.org\/10.1007\/s00262-020-02832-0.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"1256_CR48","doi-asserted-by":"publisher","first-page":"e005930","DOI":"10.1136\/jitc-2022-005930","volume":"10","author":"V Glutsch","year":"2022","unstructured":"Glutsch V, Schummer P, Kneitz H, Gesierich A, Goebeler M, Klein D, et al. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. J Immunother Cancer. 2022;10(11):e005930. https:\/\/doi.org\/10.1136\/jitc-2022-005930.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1256_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/CJI.0000000000000432","volume":"45","author":"SZ Shalhout","year":"2022","unstructured":"Shalhout SZ, Emerick KS, Kaufman HL, Silk AW, Thakuria M, Miller DM. A retrospective study of ipilimumab plus nivolumab in anti-PD-L1\/PD-1 refractory Merkel cell carcinoma. J Immunother. 2022;45(7):299\u2013302. https:\/\/doi.org\/10.1097\/CJI.0000000000000432.","journal-title":"J Immunother"},{"key":"1256_CR50","doi-asserted-by":"publisher","unstructured":"Bhakuni R, Hall ET, Gooley T, Mowery Y, Ansstas G, Brohl AS, et al. MATRiX: a randomized phase II trial of tuvusertib\/M1774 (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma. J Clin Oncol. 2026;44(Suppl 17):LBA9514. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA9514.","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA9514"},{"issue":"16_suppl","key":"1256_CR51","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1200\/JCO.2025.43.16_suppl.9531","volume":"43","author":"NJ Miller","year":"2025","unstructured":"Miller NJ, Ambrazeviciute G, Bencomo TJ, Biese K, Chen W, Church C, et al. Trick-MCC: final results from the proof-of-concept investigator-initiated study of combination therapy with anti\u2013PD-1, anti\u2013LAG-3, and anti\u2013TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma (NCT06056895). J Clin Oncol. 2025;43(16_suppl):9531. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9531.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1256_CR52","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1634\/theoncologist.2019-0877","volume":"25","author":"H Xie","year":"2020","unstructured":"Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, et al. Delta-like protein 3 expression and targeting in Merkel cell carcinoma. Oncologist. 2020;25(9):810\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0877.","journal-title":"Oncologist"},{"issue":"27","key":"1256_CR53","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, et al. Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. J Clin Oncol. 2025;43(27):3021\u201331. https:\/\/doi.org\/10.1200\/JCO-25-00363.","journal-title":"J Clin Oncol"},{"issue":"10404","key":"1256_CR54","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0140-6736(23)00769-9","volume":"402","author":"JC Becker","year":"2023","unstructured":"Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet. 2023;402(10404):798\u2013808. https:\/\/doi.org\/10.1016\/S0140-6736(23)00769-9.","journal-title":"Lancet"},{"key":"1256_CR55","doi-asserted-by":"publisher","unstructured":"Mehnert JM, Lee SJ, Gastman B, Hsu C, Cohen G, Eicher DM, et al. ECOG-ACRIN EA6174: STAMP: surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial. Ann Oncol. 2025;36(Suppl 2):S1715 (abstract LBA56). https:\/\/doi.org\/10.1016\/j.annonc.2025.09.068.","DOI":"10.1016\/j.annonc.2025.09.068"},{"issue":"Suppl 17","key":"1256_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA9505","volume":"44","author":"JM Mehnert","year":"2026","unstructured":"Mehnert JM, Lee SJ, Gastman B, Hsu CC-c, Cohen GI, Eicher DM, et al. Updated outcomes from STAMP: surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial\u2014ECOG-ACRIN EA6174. J Clin Oncol. 2026;44(Suppl 17):LBA9505. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA9505.","journal-title":"J Clin Oncol"},{"issue":"Suppl 17","key":"1256_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA9504","volume":"44","author":"S Bhatia","year":"2026","unstructured":"Bhatia S, Gooley TA, Brohl AS, Fecher LA, Chandra S, Gao L, et al. ADAM trial: a multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases. J Clin Oncol. 2026;44(Suppl 17):LBA9504. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA9504.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1256_CR58","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbe C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38(22):2476\u201387. https:\/\/doi.org\/10.1200\/JCO.20.00201.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1256_CR59","doi-asserted-by":"publisher","first-page":"e013939","DOI":"10.1136\/jitc-2025-013939","volume":"14","author":"AS Brohl","year":"2026","unstructured":"Brohl AS, Sondak VK, Wuthrick EJ, Kim Y, Eroglu Z, Markowitz J, et al. Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026;14(1):e013939.\u00a0https:\/\/doi.org\/10.1136\/jitc-2025-013939.","journal-title":"J Immunother Cancer"},{"issue":"26","key":"1256_CR60","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.23.02054","volume":"42","author":"T Akaike","year":"2024","unstructured":"Akaike T, Thakuria M, Silk AW, Hippe DS, Park SY, So NA, et al. Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications. J Clin Oncol. 2024;42(26):3151\u201361. https:\/\/doi.org\/10.1200\/JCO.23.02054.","journal-title":"J Clin Oncol"},{"key":"1256_CR61","unstructured":"Natera. Signatera\u2122 for melanoma and other skin cancers. https:\/\/www.natera.com\/oncology\/signatera-advanced-cancer-detection\/clinicians\/signatera-for-skin-cancers\/. Accessed 21 Aug 2026."},{"key":"1256_CR62","doi-asserted-by":"publisher","unstructured":"Akaike T, Thakuria M, Silk AW, Hippe DS, Ch\u2019en PY, Park SY, et al. Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management. J Am Acad Dermatol. 2026;94(2):548\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.032.","DOI":"10.1016\/j.jaad.2025.10.032"},{"issue":"1","key":"1256_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101918","volume":"11","author":"K Murchison","year":"2026","unstructured":"Murchison K, Camargo A, Margalit D, Schoenfeld JD, Tishler R, Khaddour K, et al. Circulating tumor DNA predicts response after definitive radiation therapy for Merkel cell carcinoma. Adv Radiat Oncol. 2026;11(1):101918. https:\/\/doi.org\/10.1016\/j.adro.2025.101918.","journal-title":"Adv Radiat Oncol"},{"issue":"16_suppl","key":"1256_CR64","doi-asserted-by":"publisher","first-page":"9574","DOI":"10.1200\/JCO.2025.43.16_suppl.9574","volume":"43","author":"JE Chan","year":"2025","unstructured":"Chan JE, Hippe DS, Thakuria M, Akaike T, Park SY, Silk AW, et al. Comparison of surveillance circulating tumor DNA and Merkel polyomavirus antibody titer for detection of Merkel cell carcinoma recurrence. J Clin Oncol. 2025;43(16_suppl):9574. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9574.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01256-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:00:09Z","timestamp":1791392409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01256-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":64,"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01256-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shailender Bhatia reports honoraria from Bristol Myers Squibb, Incyte, and Replimune; consulting or advisory roles for Bristol Myers Squibb, Incyte, and Replimune; research funding from Agenus, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Incyte, MSD, and TriSalus Life Sciences; and travel, accommodations, or expenses from Regeneron. Sandra D\u2019Angelo reports honoraria from Aadi, Adaptimmune, GI Innovation, GSK, Incyte, Nektar, Pfizer, Rain Therapeutics, and Servier; consulting or advisory roles for Aadi, Adaptimmune, GI Innovation, GSK, Incyte, Medendi, Nektar, Pfizer, Rain Therapeutics, and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Incyte, MSD, and Nektar; and travel, accommodations, or expenses from Adaptimmune, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, and Nektar. Paul Nghiem reports honoraria from UpToDate; consulting or advisory roles for Almirall; research funding from Incyte; and a patent pending for high-affinity T-cell receptors that target the Merkel polyomavirus (patent filed: \u201cMerkel Cell Polyomavirus T Antigen-Specific TCRs and Uses Thereof\u201d).","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}